Trial reportActa dermato-venereologica2025
Long-term Progressive Improvement of Atopic Dermatitis by an Herbal Emollient Plus Combination in a 12-week Clinical Trial.
Trial report in Acta dermato-venereologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05790083 (Assessment of the Short- and Long-Term Skin Efficacy and Tolerability of a Cosmetic Product Combination of Body Lotion and Intensive Care Over 3 Months in Subjects With Atopic Eczema), which is not on this map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Assessment of the Short- and Long-Term Skin Efficacy and Tolerability of a Cosmetic Product Combination of Body Lotion and Intensive Care Over 3 Months in Subjects With Atopic Eczema
Who cites it
3 citing papers in PubMed.
- Herbal Extracts and Plant-Derived Bioactives in Atopic Dermatitis: Evidence, Mechanisms, Pediatric Safety, and Translational Priorities.Food science & nutrition · 2026Review
- Cannabinoids for Dermatological Applications: Mechanistic Insights, Clinical Evidence, and Emerging Nanotechnology-Enabled Delivery Strategies.Pharmaceutics · 2026Review
- Cannabinoid Therapies in Less-Common Disorders: Clinical Evidence and Formulation Strategies.Diseases (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atopic dermatitis is a chronic inflammatory skin disease characterized by flare-ups of inflamed, dry, and itchy skin affecting over 200 million people worldwide. "Emollients plus" containing active cosmetic ingredients such as herbal extracts and phytochemicals have the potential to surpass the efficacy of conventional emollients, while avoiding side effects associated with pharmacological interventions. The reported 12-week clinical trial (NCT05790083) evaluated long-term efficacy and tolerability of oil-in-water emulsions BNO 3731 and BNO 3732 containing ginger extract and cannabidiol as basic emollient therapy for atopic dermatitis. A total of 100 adults and children with a history of atopic dermatitis were included and applied BNO 3732 (body lotion) twice daily and BNO 3731 (intensive care product) as needed. Over 12 weeks the emollients plus combination led to sustained improvement of peak pruritus and patient-reported outcome measures, i.e., "Recap of atopic eczema". Objective dermatological evaluation showed progressive improvements for vIGA-ADTM and isolated symptoms, i.e., erythema and dryness. Instrumental analysis of intercellular lipid contents and lipid lamellae organization in the stratum corneum demonstrated recovery of the epidermal barrier integrity. The clinical results provide evidence on the efficacy of herbal emollients plus beyond mere moisturizing and occlusive properties. BNO 3731 and BNO 3732 were very well tolerated.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.